Drug survival of apremilast in patients treated for psoriasis in a real-world setting
To the Editor: Apremilast, a phosphodiesterase 4 inhibitor, has demonstrated efficacy in treatment of psoriasis and psoriatic arthritis in the phase 3 clinical trials ESTEEM and PALACE, respectively. 1, 2 However, it is also important to examine the use of apremilast in real-world settings. The purpose of this study was to determine the failure rate and drug survival of apremilast in clinical practice.
This retrospective chart review included patients who sought treatment at the dermatology clinic Kaiser Permanente Los Angeles Medical Center, were given a psoriasis diagnosis by a dermatologist, and were treated with apremilast 30 mg twice daily with standard introductory dosing during January 1, 2015-January 11, 2018. A total of 84 patients were included in the study. Treatment failure was defined as the need to add either an oral medication (eg, methotrexate, cyclosporine, or acitretin) or phototherapy or switch to a different oral or biologic agent. The date of failure was set as the visit date at which the therapy was altered. Kaplan-Meier methodology was used to calculate probability of drug survival in the entire cohort ( persistence and loss to follow-up groups were censored) and provide comprehensive survival duration.
Our results showed that 50.0% (40/80) of patients remained on apremilast at the end of the study, with treatment durations ranging 45-1004 days (Fig 1) . The therapy for the remaining patients 50.0% (40/80) failed after an average of 198 days and median of 141 days of treatment. Three patients were lost to follow-up. Mean drug survival duration (Fig 2) was 348 (95% confidence interval 275-420) days. Median drug survival was 295 days.
While clinical trials have examined the safety and efficacy of apremilast for 52 weeks, 3 this study examines drug survival over a longer period of time in a real-world setting. The results of this study suggest a higher discontinuation rate compared with a previous study by Mayba et al, 4 which reported 16.1% (18/99) of patients stopped apremilast treatment during their study period. However, their cohort also included patients taking apremilast with other systemic medications, which could have affected persistence rates of apremilast.
Despite a relatively short study duration and a small sample size, this study offers important information regarding response durations in real-world practice. In addition, this study does not address the clinical efficacy of apremilast. The results from this study demonstrate that persistence rates appear to be similar among patients who had previously tried other systemics (48%) and those who had not (53%). Which supports the utility of apremilast as both a potential transition from topical to systemic medications and for those who have previously failed other systemic medications. While apremilast provides a nonbiologic treatment option with a favorable safety profile, some patients might eventually require additional therapy. Future studies with longer study durations and larger sample sizes would enhance generalizability of results to decision-making in clinical practice. Cumulative probability of drug survival in patients using apremilast.
